scholarly journals The Emergence of Imaging MS in Drug Discovery and Development: Making a Difference by Driving Decision Making

2021 ◽  
Author(s):  
Stephen Castellino ◽  
Nichole M. Lareau ◽  
M. Reid Groseclose
Keyword(s):  
Decision Making ◽  
Drug Discovery ◽  
Drug Discovery And Development ◽  
Making A Difference ◽  
Imaging Ms

scholarly journals MALDI Imaging MS: Molecular Visualization of Tissues in Drug Discovery and Development

2015 ◽  
Vol 21 (S3) ◽  
pp. 2229-2230 ◽  
Author(s):  
Stephen Castellino ◽  
M. Reid Groseclose
Keyword(s):  
Drug Discovery ◽  
Maldi Imaging ◽  
Molecular Visualization ◽  
Drug Discovery And Development ◽  
Imaging Ms

scholarly journals A Model‐Informed Drug Discovery and Development Strategy for the Novel Glucose‐Responsive Insulin MK‐2640 Enabled Rapid Decision Making

2020 ◽  
Vol 107 (6) ◽  
pp. 1296-1311
Author(s):  
Sandra A.G. Visser ◽  
Bhargava Kandala ◽  
Craig Fancourt ◽  
Alexander W. Krug ◽  
Carolyn R. Cho
Keyword(s):  
Decision Making ◽  
Drug Discovery ◽  
Development Strategy ◽  
The Novel ◽  
Drug Discovery And Development

Transforming Translation Through Quantitative Pharmacology for High‐Impact Decision Making in Drug Discovery and Development

2019 ◽  
Vol 107 (6) ◽  
pp. 1285-1289 ◽  
Author(s):  
Neeraj Gupta ◽  
Dean Bottino ◽  
Ulrika S.H. Simonsson ◽  
Cynthia J. Musante ◽  
Tjerk Bueters ◽  
...  
Keyword(s):  
Decision Making ◽  
Drug Discovery ◽  
High Impact ◽  
Drug Discovery And Development ◽  
Quantitative Pharmacology

scholarly journals Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis

BMC Biology ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Feixiong Cheng ◽  
Yifang Ma ◽  
Brian Uzzi ◽  
Joseph Loscalzo
Keyword(s):  
Decision Making ◽  
Drug Discovery ◽  
Network Analysis ◽  
Pharmaceutical Industry ◽  
Health Care Providers ◽  
Scientific Collaboration ◽  
Knowledge Flows ◽  
Public Understanding ◽  
Care Providers ◽  
Drug Discovery And Development

Abstract Background Growing evidence shows that scientific collaboration plays a crucial role in transformative innovation in the life sciences. For example, contemporary drug discovery and development reflects the work of teams of individuals from academic centers, the pharmaceutical industry, the regulatory science community, health care providers, and patients. However, public understanding of how collaborations between academia and industry catalyze novel target identification and first-in-class drug discovery is limited. Results We perform a comprehensive network analysis on a large scientific corpus of collaboration and citations (97,688 papers with 1,862,500 citations from 170 million scientific records) to quantify the success trajectory of innovative drug development. By focusing on four types of cardiovascular drugs, we demonstrate how knowledge flows between institutions to highlight the underlying contributions of many different institutions in the development of a new drug. We highlight how such network analysis could help to increase industrial and governmental support, and improve the efficiency or accelerate decision-making in drug discovery and development. Conclusion We demonstrate that network analysis of large public databases can identify and quantify investigator and institutional relationships in drug discovery and development. If broadly applied, this type of network analysis may help to enhance public understanding of and support for biomedical research, and could identify factors that facilitate decision-making in first-in-class drug discovery among academia, the pharmaceutical industry, and healthcare systems.

The Moraceae family: an important source of drug discovery and development

Planta Medica ◽  
2015 ◽  
Vol 81 (05) ◽  
Author(s):  
AJ Hou
Keyword(s):  
Drug Discovery ◽  
Drug Discovery And Development

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

Sign in / Sign up

Export Citation Format

Share Document